S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: Tiny biotech successfully treats blindness (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
BREAKING: Tiny biotech successfully treats blindness (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: Tiny biotech successfully treats blindness (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
BREAKING: Tiny biotech successfully treats blindness (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: Tiny biotech successfully treats blindness (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
BREAKING: Tiny biotech successfully treats blindness (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: Tiny biotech successfully treats blindness (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
BREAKING: Tiny biotech successfully treats blindness (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:CVAC

CureVac (CVAC) Competitors

$9.15
-0.28 (-2.97%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$9.06
▼
$9.49
50-Day Range
$6.43
▼
$10.46
52-Week Range
$5.63
▼
$19.67
Volume
373,200 shs
Average Volume
962,002 shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

CVAC vs. VTYX, SDGR, AMPH, SUPN, PCRX, HRMY, BLU, AMLX, BHC, and MORF

Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Ventyx Biosciences (VTYX), Schrödinger (SDGR), Amphastar Pharmaceuticals (AMPH), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Harmony Biosciences (HRMY), BELLUS Health (BLU), Amylyx Pharmaceuticals (AMLX), Bausch Health Companies (BHC), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.

CureVac vs.

CureVac (NASDAQ:CVAC) and Ventyx Biosciences (NASDAQ:VTYX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.

95.6% of Ventyx Biosciences shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 24.4% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CureVac's return on equity of 0.00% beat Ventyx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac N/A N/A N/A
Ventyx Biosciences N/A -36.87% -34.54%

In the previous week, CureVac had 4 more articles in the media than Ventyx Biosciences. MarketBeat recorded 7 mentions for CureVac and 3 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.90 beat CureVac's score of 0.37 indicating that Ventyx Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CureVac
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ventyx Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ventyx Biosciences has lower revenue, but higher earnings than CureVac.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$72.33 million28.32-$262.38 millionN/AN/A
Ventyx BiosciencesN/AN/A-$108.43 million-$2.28-15.11

CureVac received 4 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 55.26% of users gave CureVac an outperform vote while only 53.13% of users gave Ventyx Biosciences an outperform vote.

CompanyUnderperformOutperform
CureVacOutperform Votes
21
55.26%
Underperform Votes
17
44.74%
Ventyx BiosciencesOutperform Votes
17
53.13%
Underperform Votes
15
46.88%

CureVac currently has a consensus target price of $21.00, indicating a potential upside of 129.51%. Ventyx Biosciences has a consensus target price of $55.40, indicating a potential upside of 60.77%. Given CureVac's higher probable upside, equities research analysts clearly believe CureVac is more favorable than Ventyx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ventyx Biosciences
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

CureVac has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of -0.35, meaning that its share price is 135% less volatile than the S&P 500.

Summary

CureVac beats Ventyx Biosciences on 8 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVAC vs. The Competition

Export to Excel
MetricCureVacPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.05B$5.82B$4.58B$6.18B
Dividend YieldN/A2.72%2.32%6.15%
P/E RatioN/A9.82114.5614.51
Price / Sales28.32322.773,689.0487.19
Price / CashN/A20.5598.32107.27
Price / Book3.185.095.047.13
Net Income-$262.38M$188.69M$118.58M$192.91M
7 Day Performance-5.38%-2.49%1.10%0.20%
1 Month Performance24.15%1.52%1.28%1.33%
1 Year Performance-52.71%17.02%19.57%-0.24%

CureVac Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTYX
Ventyx Biosciences
2.0435 of 5 stars		$34.30
-4.7%		$55.40
+61.5%		+83.8%$1.95BN/A-16.7327
SDGR
Schrödinger
2.0315 of 5 stars		$27.01
-2.4%		$50.00
+85.1%		+35.8%$1.92B$197.07M207.79664
AMPH
Amphastar Pharmaceuticals
1.9726 of 5 stars		$42.94
+2.8%		$40.00
-6.8%		+13.6%$2.07B$498.99M24.401,615
SUPN
Supernus Pharmaceuticals
2.6149 of 5 stars		$35.16
+1.2%		$46.00
+30.8%		+18.4%$1.92B$667.24M34.14575
PCRX
Pacira BioSciences
2.2665 of 5 stars		$41.27
-2.8%		$62.73
+52.0%		-38.8%$1.90B$669.17M-152.85697Positive News
HRMY
Harmony Biosciences
3.0774 of 5 stars		$35.90
-1.8%		$62.89
+75.2%		-18.5%$2.15B$471.67M11.58180Positive News
BLU
BELLUS Health
2.0138 of 5 stars		$14.44
-0.2%		$16.50
+14.3%		+75.8%$1.83B$15,000.00-22.2240Positive News
AMLX
Amylyx Pharmaceuticals
2.5356 of 5 stars		$27.18
-3.4%		$50.50
+85.8%		+182.8%$1.82B$22.23M-7.9234Short Interest ↑
BHC
Bausch Health Companies
1.9582 of 5 stars		$6.02
-0.2%		$8.67
+44.0%		-17.5%$2.18B$8.15B-6.1419,900
MORF
Morphic
1.9802 of 5 stars		$55.30
-3.9%		$70.33
+27.2%		+143.6%$2.19B$68.95M-33.72101Short Interest ↑
Gap Down

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:CVAC) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -